ClinicalTrials.gg
RecruitingNCT04587739KARCHER-1Updated Oct 26, 2026

Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.

A Phase 1 interventional study of Surgery with Neoadjuvant stereotactic body radiation therapy in Hepatocellular Carcinoma, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University Hospital, Lille · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 284 studies in Carcinoma, Hepatocellular with a site in France — 54 open to participants now, 85 under way, 14 of them phase 3. Carcinoma, Hepatocellular · France.

Planned enrollment
170th of 215
30 · median 136
Started
2021
with 18 others
Phase 1
27 of 284
5 open now
Primary completion
2028-01
later than 52 of 84 live
Registered
186th of 284
by date

Among the 284 studies in Carcinoma, Hepatocellular with a site in France, this one is the 170th largest by planned enrollment of the 215 interventional ones that give a count, is one of 19 that started in 2021, is one of 27 in phase 1, reaches primary completion later than 52 of the 84 other live ones, and was the 186th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

54 of the 284 studies in Carcinoma, Hepatocellular with a site in France are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Carcinoma, Hepatocellular with a site in France, or all of them as a file.
02

Study summary

Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-called "microvascular invasion".

To adequately deal with this phenomenon, the surgeon has to perform either an 'anatomical' liver resection, which remove not only the tumor but also the whole corresponding vascular network, or a 'tumorectomy' with resection margins of at least 2 cm. Unfortunately, these principles cannot always be achieved due to underlying liver cirrhosis that is present in more than 80% of patients.

Stereotactic body radiation therapy (SBRT) has been proven to efficiently necrotize or stabilize HCC nodules when surgery is not possible. Our hypothesis is that pre-treatment with SBRT prior to surgical resection of HCC might improve the results through the destruction of possible seeding in the peritumoral environment.

Given the novelty of this therapeutic strategy, it is necessary to verify its feasibility and safety, prior to test its efficacy in patients with HCC. The KARCHeR-1 study aims at making sure that preoperative SBRT would not result in important delays or serious adverse events such as to cancel the planned surgical resection, in patients who otherwise could have benefited from it. This issue is commonly called 'drop-out'. Thirty patients are expected to be included in the KARCHeR-1 study, which would be in favor of continuing to evaluate this therapeutic strategy if less than 3 drop-outs occur, and would be immediately discontinued if 3 drop-outs occur. Other outcomes will also been studied, like intraoperative issues, postoperative morbi-mortality, pathological features on the surgical specimen and its correlation with preoperative imaging, and finally, tumor recurrence and survival.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular carcinoma
  • Stereotactic body radiation therapy
  • Hepatectomy
  • Neoadjuvant therapy
  • Drop-out
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven hepatocellular carcinoma or EASL/AASLD criteria
  • Single nodule, 3 to 8 cm of largest diameter
  • Hepatocellular carcinoma eligible for conventional liver resection with curative intent (R0), without preoperative portal vein embolization

Exclusion criteria

Exclusion Criteria:

  • Performance status > 2
  • Severe comorbidity with for either surgery or radiation therapy
  • Decompensated liver cirrhosis ( B or C)
  • Neoplastic portal vein thrombosis or extra-hepatic
  • Previous anticancer therapy within the last 5 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Combination Product: Surgery with Neoadjuvant stereotactic body radiation therapy

Interventions

  • Combination productSurgery with Neoadjuvant stereotactic body radiation therapy

    Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).

06

What researchers measure

Primary outcomes

  1. Drop-out rate

    Drop-out rate: proportion of patients in whom surgical resection cannot be achieved, due to (at least one of the following reasons): * serious adverse events related to radiation therapy (especially liver decompensation); * disease progression while receiving radiation therapy or awaiting surgery; * patient's death.

    Time frame: Five months after the inclusion of the last participating patient

Secondary outcomes

  1. Intraoperative number of packed red blood cells transfused (if any).

    Time frame: Postoperative 90 days

  2. Toxicity of radiation therapy using the National Cancer Institute CTCAE v.5.0 criteria

    Time frame: Postoperative 90 days

  3. Duration of surgery.

    Time frame: Postoperative 90 days

  4. Volume of intraoperative blood loss

    Time frame: Postoperative 90 days

  5. Quality of life by EORTC QLQ-C30

    Time frame: between before and after stereotactic radiotherapy

  6. Intraoperative adverse events

    Time frame: Postoperative 90 days

  7. Postoperative severe and overall morbidity rate

    defined using the Comprehensive Complication Index and graded with the Dindo-Clavien score

    Time frame: Postoperative 90 days

  8. Postoperative mortality rate.

    Time frame: Postoperative 90 days

  9. Correlation between radiological observations on preoperative imaging and pathological features on surgical specimen (like percentage of tumor necrosis).

    Time frame: Postoperative day 30.

  10. Actuarial overall survival and disease-free survival.

    Time frame: Postoperative 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jan 2028, 84 months after the start.

Of 147 non-industry phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 80. This study's planned 84 months is above that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2020
First posted
Oct 14, 2020
StartActual
Jan 31, 2021
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04587739
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Jan 31, 2021
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Emmanuel Boleslawski, MD,PhD
Contact
emmanuel.boleslawski@chru-lille.fr
320444260 ext. +33
Emmanuel Boleslawski, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion